LEXOTAN TABLET 1.5mg

Product Information

Registration Status: Active

LEXOTAN TABLET 1.5mg is approved to be sold in Singapore with effective from 1988-04-27. It is marketed by DKSH SINGAPORE PTE LTD, with the registration number of SIN00385P.

This product contains Bromazepam 1.5mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by Roche S.p.A. in ITALY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Bromazepam

Description

One of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepines.

Indication

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

Mechanism of Action

Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.

Pharmacokinetics

Absorption
Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.
Distribution
1.56 L/kg
Metabolism
Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.
Elimination

Clearance

0.82 mL/min/kg.

Active Ingredient/Synonyms

Bromazepamum | Lectopam | Bromazepam |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank